Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in ...

SIL204 demonstrated dose-dependent inhibition of up to 94% in pancreatic cancer cells harboring KRAS G12D mutations at nanomolar concentrations. SIL204 showed comparable efficacy of approximately 97% ...

Silexion Therapeutics Corp (NASDAQ:SLXN) shares are moving higher on Wednesday after the company reported that Guangzhou Sino-Israel bio-industry investment fund holds a stake in the company. The ...

) has been revised to $6.12 / share. This is a decrease of 33.33% from the prior estimate of $9.18 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three ...

Silexion (SLXN) market outlook | growth forecasts and investor confidence remain in focus. Silexion Therapeutics Corp (SLXN) ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...